Valneva SE (NAS:VALN) ROCE %

: -52.26% (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Valneva SE's annualized ROCE % for the quarter that ended in Dec. 2022 was -52.26%.

Valneva SE ROCE % Historical Data

The historical data trend for Valneva SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

4.14

0.85

-22.86

-14.28

-30.59

Valneva SE Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %																159.81	-16.01	-197.41	98.05	-52.26

Valneva SE ROCE % Calculation

Valneva SE's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-133.22139830508	/	( ( (923.5615819209 - 416.92542372881)	+	(658.20338983051 - 293.84851694915) )	/ 2 )
	=	-133.22139830508	/	( (506.63615819209	+	364.35487288136)	/ 2 )
	=	-133.22139830508	/	435.49551553672
	=	-30.59 %

Valneva SE's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	-179	/	( ( (691.17128712871 - 370.50693069307)	+	(658.20338983051 - 293.84851694915) )	/ 2 )
	=	-179	/	( ( 320.66435643564	+	364.35487288136 )	/ 2 )
	=	-179	/	342.5096146585
	=	-52.26 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

Valneva SE (NAS:VALN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Valneva SE ROCE % Related Terms

Thank you for viewing the detailed overview of Valneva SE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (NAS:VALN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

INRLF:USA VLA:France AYJ:Germany

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.